Publication: CARMELINA Elderly Subgroup Analysis [1]
Review the long-term safety profile of Trajenta® among age groups.
Publication: CAROLINA Asian Subgroup Analysis [2]
Review the long-term safety profile of Trajenta® in Asian patients.
Simple. Every Day.
When a DPP4i is needed, choose the Simplicity of Trajenta®.
10 Years of Simplicity
Browse through an interactive infographic showcasing the clinical development and significant accomplishments for Trajenta®.
In 2011, Trajenta® (linagliptin) became first approved by regulatory agencies around the world, as a once-daily, always one-dose, DPP4i for the treatment of type 2 diabetes*. For the past 10 years, the simplicity of Trajenta® has helped physicians and patients with the management of type 2 diabetes for a broad range of patients1. In that time, Trajenta® has had more than 20 million patient-years of exposure2, and it continues to be an important tool for healthcare professionals worldwide3.
This year, in commemoration of the past 10 years, we organized a 2-hour webcast, the 10 Years of Simplicity. The event took place on the 27th of May 2021. During the interactive webcast, we discussed Trajenta® and how 10 years of experience have helped simplify the management of type 2 diabetes for physicians and patients worldwide. Participants heard perspectives from leading international experts in the treatment of type 2 diabetes. Continue below to learn more about the event.
Meet the Experts
Professor
Per-Henrik Groop
Professor and Chair of Internal Medicine at the University of Helsinki and & Chief Physician at the Helsinki University Hospital
Doctor
Sarah Jarvis
General Practitioner (GP), GP Trainer and Fellow of the Royal College of General Practitioners (RCGP)
Professor
Clifford J. Bailey
Professor of Clinical Science and Director of Biomedical Sciences Research at Aston University in Birmingham, England
Professor
Nikolaus Marx
Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I, University Hospital Aachen, Germany
Agenda
Download linkWelcome to 10 Years of Trajenta®
Per-Henrik Groop and Sarah Jarvis
- Webcast objectives and introduction of Chair
10 Years of Improvement in T2D Patient Care
Clifford J. Bailey
- Chair to introduce faculty
- Paradigm shift in T2D guidelines based on evidence of proven CV benefit
- The role of DPP4i in treatment of T2D and the evolution of the Trajenta® profile (proven efficacy1, convenience, followed by CV and kidney safety from CVOTs)
CARMELINA® and CAROLINA®: An Extensive Dataset From A Unique CVOT Programme
Nikolaus Marx
- Robust CV and kidney safety data from CARMELINA® and CAROLINA® in patients across a broad spectrum of T2D disease duration, CV and kidney risk
- Trajenta® is the only DPP4i with 2 large CVOTs, including an active-comparator trial
Can A Broad Range of T2D Patients Benefit From The Simplicity of Linagliptin?
Per-Henrik Groop
- Proven efficacy1 for a broad range of patients, and convenience of always one dose, once daily
- Data from CARMELINA® and CAROLINA® subgroup analyses support CV and kidney safety profile of Trajenta® and continue to generate scientific evidence from the CVOT programme
Defining Simplicity in Clinical Practice – A Case-Driven Approach
Sarah Jarvis
- Patient cases incorporating speaker experience with Trajenta®
- Data from Trajenta® CVOTs support treatment decision making
Summarising The Advances That Linagliptin Has Brought to T2D Care
Per-Henrik Groop
- Vast experience with Trajenta®
- Highlights of Trajenta® simplicity (efficacy, safety, convenience)
Q&A and Close
Per-Henrik Groop and Sarah Jarvis
- Audience Q&A
- Moderator to reinforce the simplicity of Trajenta® and close the webcast
Welcome to 10 Years of Trajenta®
Per-Henrik Groop and Sarah Jarvis
- Webcast objectives and introduction of Chair
10 Years of Improvement in T2D Patient Care
Clifford J. Bailey
- Chair to introduce faculty
- Paradigm shift in T2D guidelines based on evidence of proven CV benefit
- The role of DPP4i in treatment of T2D and the evolution of the Trajenta® profile (proven efficacy1, convenience, followed by CV and kidney safety from CVOTs)
CARMELINA® and CAROLINA®: An Extensive Dataset From A Unique CVOT Programme
Nikolaus Marx
- Robust CV and kidney safety data from CARMELINA® and CAROLINA® in patients across a broad spectrum of T2D disease duration, CV and kidney risk
- Trajenta® is the only DPP4i with 2 large CVOTs, including an active-comparator trial
Can A Broad Range of T2D Patients Benefit From The Simplicity of Linagliptin?
Per-Henrik Groop
- Proven efficacy1 for a broad range of patients, and convenience of always one dose, once daily
- Data from CARMELINA® and CAROLINA® subgroup analyses support CV and kidney safety profile of Trajenta® and continue to generate scientific evidence from the CVOT programme
Defining Simplicity in Clinical Practice – A Case-Driven Approach
Sarah Jarvis
- Patient cases incorporating speaker experience with Trajenta®
- Data from Trajenta® CVOTs support treatment decision making
Summarising The Advances That Linagliptin Has Brought to T2D Care
Per-Henrik Groop
- Vast experience with Trajenta®
- Highlights of Trajenta® simplicity (efficacy, safety, convenience)
Q&A and Close
Per-Henrik Groop and Sarah Jarvis
- Audience Q&A
- Moderator to reinforce the simplicity of Trajenta® and close the webcast
Footnotes
- DPP4i: dipeptidyl peptidase-4 inhibitor; T2D: type 2 diabetes
- * Tradjenta® was approved by the US Food and Drug Administration (FDA) on May 2nd, 2011; Trazenta® was approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) on July 1st, 2011; Trajenta® was approved by the European Medicines Agency (EMA) on August 23rd, 2011; Trajenta® was approved by Health Canada on October 3rd, 2011; Trajenta® was approved by the Australian Therapeutic Goods Administration (TGA) on October 21st, 2011.
- Trajenta® EMA Summary of Product Characteristics. October 2019.
- Boehringer Ingelheim. Data on file.
- American Diabetes Association. Diabetes Care 2021 Jan; 44 (Supplement 1): S111-S124. https://doi.org/10.2337/ dc21-S009.